| Gene symbol | CD59 | Synonyms | 16.3A5, 1F5, EJ16, EJ30, EL32, G344, HRF-20, HRF20, MAC-IP, MACIF, MEM43, MIC11, MIN1, MIN2, MIN3, MIRL, MSK21, p18-20 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11p13 | dbXrefs | |
| Description | CD59 molecule (CD59 blood group) | ||||
| GTO ID | GTC0372 |
| Trial ID | NCT03144999 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | CD59 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | HMR59 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAVCAGsCD59 in Patients With Advanced Non-Exudative (Dry) Age-Related Macular Degeneration With Geographic Atrophy |
| Year | 2017 |
| Country | United States |
| Company sponsor | Janssen Research & Development, LLC |
| Other ID(s) | HMR-1001 |
| Vector information | |||||||||||
|
|||||||||||
| Cohort 1 | |||||||||||||
|
|||||||||||||